Skip to main content
CADL logo

CADL · Candel Therapeutics, Inc.

Track CADL — free
$5.16 -0.16 (-3.04%)
Market Cap
$402.43M
Shares
78.45M
Volume · Nov 19 1.16M Avg daily vol (3M) 1.26M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.13 Open$5.38 Day$5.07–5.45 52W close$4.42–13.75 Avg vol 30d1.4M Short int13.1M · 16.7% of shares · 13.3d Short vol46% Last earningsMay 20, 2026 DataJul 2021–Nov 2026 Filing10-Q · Nov 12

Up next

Feb 23, 2028 Est · unconfirmed · in 66 wks

Latest documents

2026
Nov 18
Investor event
BLA completion delayed to mid-2027 by six-month assay validation

Candel's CEO said the company learned on November the 9th that validating the IU assay would take six months, pushing BLA completion to mid-2027. The delay is analytical rather than manufacturing-related, and the CV must consistently stay below 30%. The launch target moves from Q4, 2027 to Q1, 2028.

9 source passages
And then it came to my attention, actually, I know exactly when, November the 9th at 9.30 So that takes six months. I know exactly when, November the 9th at 9.30 is mid-2027, is that the expected timing for the complete BLA submission? This has nothing to do with manufacturing. and the CV needs to be consistently lower than 30%. We have successfully developed it, the IU assay. we were aiming for launch in Q4, 2027. So now we aim for launch in Q1, 2028 Open the document at this passage
Nov 18
Investor event
Potency assay validation delays BLA filing by six months

Candel Therapeutics said it became aware on November the 9th that validation of its potency assay would take six months. The company said the delay is analytical rather than manufacturing-related, and the coefficient of variability must be consistently lower than 30%. Launch is now targeted for Q1, 2028, and the cash runway extends into the second quarter of 2028.

7 source passages
Candel Therapeutics develops viral immunotherapies we became aware of this on November the 9th it will take six months This has nothing to do with manufacturing the CV needs to be consistently lower than 30% we aim for launch in Q1, 2028 the expected cash runway into the second quarter of 2028 Open the document at this passage
Nov 12
Current report 8-K
New $50,000,000 common stock ATM offering

On November 12, 2026, Candel Therapeutics, Inc. entered a new at-the-market agreement with Jefferies LLC for up to $50,000,000 of common stock, after selling approximately $50,000,000 under its 2025 agreement. Jefferies receives a 3.0% commission on gross proceeds.

Other events Read from the first part of this long document
3 source passages
On November 12, 2026, Candel Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Open Market Sale Agreement^SM^ (the “2026 Sales Agreement”), with Jefferies LLC (“Jefferies”), to sell shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), from time to time through Jefferies acting as sales agent, having an aggregate offering price of up to $50,000,000 (such amount to be in addition to the aggregate gross sales proceeds received by the Company from the sale of Common Stock prior to the date hereof pursuant to the 2025 Sale Agreement (as defined below)) (the “ATM Shares”). As of November 12, 2026, the Company had sold an aggregate of approximately $50,000,000 of ATM Shares under the 2025 Sale Agreement. The 2026 Sales Agreement provides that Jefferies will be entitled to a fixed commission rate of 3.0% of the gross proceeds of the ATM Shares sold under the 2026 Sales Agreement. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Aglatimagene improved prostate survival; pancreatic program paused

Candel Therapeutics said aglatimagene achieved a 39% improvement in prostate cancer-specific disease-free survival at 58.0 months median follow-up, plans a BLA submission in the middle of 2027, and paused pancreatic cancer development.

Read from the MD&A section
4 source passages
In December 2020, we formally changed our name from Advantagene to Candel Therapeutics, Inc. Among the 745 patients enrolled in the randomized, double-blind, placebo-controlled trial, the aglatimagene arm exhibited a 39% improvement in prostate cancer-specific disease-free survival (PCa-specific DFS) compared to placebo after a median follow-up of 58.0 months. Due to timelines associated with certain assay refinement, we currently plan to submit this BLA in the middle of 2027 pending the result of that dialogue. In October 2025, we decided to pause on further clinical development of aglatimagene in PDAC, in the context of portfolio prioritization, unless externally funded through a grant or other non-dilutive external funding. Open the document at this passage
Nov 12
Current report 8-K
Aglatimagene BLA submission planned for middle 2027

Candel Therapeutics plans to submit aglatimagene’s prostate cancer BLA in the middle of 2027 pending FDA dialogue, while $203.1 million in cash is expected to fund operations into Q2 2028. Third-quarter 2026 net loss widened to $21.9 million from $11.3 million.

Financial results
3 source passages
The Company is in ongoing dialogue with the FDA regarding the submission of a Biologics License Application (BLA) for aglatimagene in prostate cancer. Due to timelines associated with certain assay refinement, the Company currently plans to submit this BLA in the middle of 2027 pending the result of that dialogue. Cash and cash equivalents of $203.1 million, as of September 30, 2026, are expected to be sufficient to fund the Company’s current operating plan into Q2 2028. Net Loss: Net loss for the third quarter of 2026 was $21.9 million compared to net loss of $11.3 million for the third quarter of 2025 and included net other income of $1.1 million and $1.9 million, respectively. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$99.14M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-16.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+41.0%
Year over year · more shares
Price change (1Y)
+15.2%
Trailing year
Short interest
16.7%
Latest settlement · 13.3 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −39%
below
Price vs 50-day avg −44%
below
RSI (14) 26
oversold
MACD trend Negative
52-week position 8%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −39%
trailing
6-month return −40%
trailing
YTD return −9%
this year
Relative strength −34%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +23 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.68% of shares out · ▲ +2.5% MoM · 13.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
142 holders — near 3-yr high, broad support
Squeeze score 73
high risk · 0–100
Fundamentals
Fair
Revenue growth 0%
Y/Y
EPS growth +59%
Y/Y
Free cash flow $-38.9M
Quant / Vol
risk profile
Very High
Volatility 78%
annualized · 1-yr
Max drawdown −63%
past year
ATR 14.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−39% Bearish
Price vs 50-day avg
−44% Bearish
RSI (14)
26 Neutral
MACD trend
Negative Bearish
52-week position
8% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +23 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.68% of shares out · ▲ +2.5% MoM · 13.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
142 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $5 · 8% Range high $14
vs 200-day avg -39% vs 50-day avg -44%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Median follow-up (Arms A+B, linoserpaturev rHGG phase 1b) 68.6 Q3 2026 —
Median overall survival (mOS), phase 2a aglatimagene plus valacyclovir in stage III/IV NSCLC 24.5 Q3 2026 —
mOS (Arm C, linoserpaturev rHGG phase 1b) 14.3 Q3 2026 —
mOS (Arms A+B, linoserpaturev rHGG phase 1b) 12 Q3 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CADL
Candel Therapeutics, Inc.
this stock
$402.43M -9.2% +0.0% — 16.7%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
142
% held
64.9%
Net QoQ
+530.2K sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
119
View
Short & Settlement
Short Interest Rising
Shares short
13.1M
Days to cover
13.3d
Change
+314.9K sh
View
Short Volume
Short vol %
46%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
39.3K
Value
$340.1K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
45.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$125.0K
Net income (FY)
$-38.2M
EPS diluted
$-0.72
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
26

Candel's CEO said the company learned on November the 9th that validating the IU assay would take six months, pushing BLA completion to mid-2027. The delay is analytical rather than manufacturing-related, and the CV must consistently stay below 30%. The launch target moves from Q4, 2027 to Q1, 2028.

View
Proposed Sales
Value
$3.4M
Shares
280.2K
Filed
Sep 10, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Candel Therapeutics Reports Third…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
CADL -38.9% -38.8% -39.7% -38.4% -9.2%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -33.4% -32.5% -34.1% -33.2% -14.2%
Key facts CIK 1841387 CUSIP 137404109 13F (30d) 151 filings 137 filers Visit website Investor relations